“We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination,” said Mathai Mammen, global head of research and development at J&J’s Janssen subsidiary.
The company said that clinical trials found a booster shot of its one-dose vaccine increased Covid-19 antibodies ninefold one month after vaccination, compared to the levels seen one month after the first shot. J&J said this was true for people 18-55 as well as those over 65, who received a lower booster dose.
J&J has submitted two papers describing the results to an online archive, but the analyses have not yet undergone peer review.
Findings released this month from a South African study of nearly 480,000 health care workers found J&J’s single-shot regimen was strongly protective against the Delta variant, cutting the risk of hospitalization by 71 percent and of death by 96 percent.
Discover more from Today Headline
Subscribe to get the latest posts to your email.